Risk of methaemoglobinaemia with OTC oral benzocaine

Risk of methaemoglobinaemia with OTC oral benzocaine Reactions 1704, p3 - 2 Jun 2018 Risk of methaemoglobinaemia with OTC oral benzocaine The US FDA has published a Drug Safety Communication warning that the use of over-the- counter (OTC) oral medications containing benzocaine may be associated with methaemoglobinaemia. Benzocaine is a local anaesthetic which may be used for the temporary relief of pain, such as that associated with soreness, injury or minor irritation of the mouth and throat. Formulations include gels, lozenges, ointments, solutions and sprays. The FDA warns than benzocaine products should not be used in patients <2 years of age. Manufacturers are urged to stop marketing the products for the treatment of teething in young children; lack of compliance may result in removal of the products from the market. Labelling changes for use in older patients include adding a warning about methaemoglobinaemia, and adding contraindications and revising the directions for use in teething and in patients <2 years of age. A standardised methaemoglobinaemia warning will be included in the prescribing information for all prescription local anaesthetics. Consumers using benzocaine products are advised to seek medical attention if signs of symptoms occur. These include the following: shortness of breath; headache; fatigue; confusion; or pale, grey or blue- coloured skin, lips and nail beds. Symptoms may appear within minutes of use, or within 1 2 hours. Healthcare professionals should warn patients about the potential risk, particularly in those with breathing problems or heart disease, or the elderly. Investigation of safety issues will continue, and the public will be updated if additional information becomes available. Patients and healthcare professionals are urged to report any further adverse events involving benzocaine to the FDA MedWatch program. * Brand names include Anbesol, Hurricaine, Orabase, Oragel and Baby Oragel, and Topex. US Food & Drug Administration. Oral Over-the-Counter Benzocaine Products: Drug Safety Communication - Risk of Serious and Potentially Fatal Blood Disorder Internet Document : 23 May 2018. Available from: URL: https:// www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm608612.htm 803323901 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Risk of methaemoglobinaemia with OTC oral benzocaine

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/risk-of-methaemoglobinaemia-with-otc-oral-benzocaine-O6CNrsDSEQ
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46646-8
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p3 - 2 Jun 2018 Risk of methaemoglobinaemia with OTC oral benzocaine The US FDA has published a Drug Safety Communication warning that the use of over-the- counter (OTC) oral medications containing benzocaine may be associated with methaemoglobinaemia. Benzocaine is a local anaesthetic which may be used for the temporary relief of pain, such as that associated with soreness, injury or minor irritation of the mouth and throat. Formulations include gels, lozenges, ointments, solutions and sprays. The FDA warns than benzocaine products should not be used in patients <2 years of age. Manufacturers are urged to stop marketing the products for the treatment of teething in young children; lack of compliance may result in removal of the products from the market. Labelling changes for use in older patients include adding a warning about methaemoglobinaemia, and adding contraindications and revising the directions for use in teething and in patients <2 years of age. A standardised methaemoglobinaemia warning will be included in the prescribing information for all prescription local anaesthetics. Consumers using benzocaine products are advised to seek medical attention if signs of symptoms occur. These include the following: shortness of breath; headache; fatigue; confusion; or pale, grey or blue- coloured skin, lips and nail beds. Symptoms may appear within minutes of use, or within 1 2 hours. Healthcare professionals should warn patients about the potential risk, particularly in those with breathing problems or heart disease, or the elderly. Investigation of safety issues will continue, and the public will be updated if additional information becomes available. Patients and healthcare professionals are urged to report any further adverse events involving benzocaine to the FDA MedWatch program. * Brand names include Anbesol, Hurricaine, Orabase, Oragel and Baby Oragel, and Topex. US Food & Drug Administration. Oral Over-the-Counter Benzocaine Products: Drug Safety Communication - Risk of Serious and Potentially Fatal Blood Disorder Internet Document : 23 May 2018. Available from: URL: https:// www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm608612.htm 803323901 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off